MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
作者信息
Kühn Michael W M, Hadler Michael J, Daigle Scott R, Koche Richard P, Krivtsov Andrei V, Olhava Edward J, Caligiuri Michael A, Huang Gang, Bradner James E, Pollock Roy M, Armstrong Scott A
机构信息
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Epizyme, Inc., Cambridge, MA, USA.
出版信息
Haematologica. 2015 May;100(5):e190-3. doi: 10.3324/haematol.2014.115337. Epub 2015 Jan 16.
Abstract
摘要
相似文献
1
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.混合谱系白血病（MLL）部分串联重复白血病细胞对小分子DOT1L抑制敏感。
Haematologica. 2015 May;100(5):e190-3. doi: 10.3324/haematol.2014.115337. Epub 2015 Jan 16.
2
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.DOT1L 和 Menin 抑制剂在 MLL 重排白血病中的协同作用。
Leukemia. 2017 Jun;31(6):1269-1277. doi: 10.1038/leu.2016.327. Epub 2016 Nov 14.
3
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.抑制赖氨酸特异性去甲基化酶1（LSD1）的药理学作用用于治疗混合系白血病重排（MLL-rearranged）白血病
J Hematol Oncol. 2016 Mar 12;9:24. doi: 10.1186/s13045-016-0252-7.
4
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.强效抑制 DOT1L 治疗 MLL 融合白血病。
Blood. 2013 Aug 8;122(6):1017-25. doi: 10.1182/blood-2013-04-497644. Epub 2013 Jun 25.
5
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.DOT1L抑制SIRT1介导的表观遗传沉默，以维持MLL重排白血病中的白血病基因表达。
Nat Med. 2015 Apr;21(4):335-43. doi: 10.1038/nm.3832. Epub 2015 Mar 30.
6
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.Mll部分串联重复通过特定的表观遗传改变在体内诱导异常的Hox表达。
J Clin Invest. 2006 Oct;116(10):2707-16. doi: 10.1172/JCI25546. Epub 2006 Sep 14.
7
The MLL partial tandem duplication in acute myeloid leukaemia.急性髓系白血病中的MLL部分串联重复
Br J Haematol. 2006 Nov;135(4):438-49. doi: 10.1111/j.1365-2141.2006.06301.x. Epub 2006 Sep 11.
8
Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.嘧啶基氨基喹啉衍生物作为 DOT1L 抑制剂的设计、合成及抗白血病细胞增殖活性。
Bioorg Chem. 2018 Oct;80:649-654. doi: 10.1016/j.bioorg.2018.07.022. Epub 2018 Jul 21.
9
Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.基于 AlphaLISA 的高通量筛选测定法发现有效的 DOT1L 抑制剂。
Bioorg Med Chem. 2018 May 1;26(8):1751-1758. doi: 10.1016/j.bmc.2018.02.020. Epub 2018 Feb 24.
10
The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.MLL部分串联重复的初始水平影响急性髓系白血病患者的临床结局。
Leuk Lymphoma. 2018 Apr;59(4):967-972. doi: 10.1080/10428194.2017.1352091. Epub 2017 Jul 26.
引用本文的文献
1
Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.选择合适的细胞系进行急性髓系白血病（AML）研究。
Int J Mol Sci. 2023 Mar 11;24(6):5377. doi: 10.3390/ijms24065377.
2
The Role of DOT1L in Normal and Malignant Hematopoiesis.DOT1L在正常和恶性造血中的作用。
Front Cell Dev Biol. 2022 May 26;10:917125. doi: 10.3389/fcell.2022.917125. eCollection 2022.
3
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.将急性髓细胞白血病发病机制的最新进展转化为临床实践。
Genes Dev. 2022 Mar 1;36(5-6):259-277. doi: 10.1101/gad.349368.122.
4
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.急性髓系白血病特定基因组异常的新兴靶向治疗。
Int J Mol Sci. 2022 Feb 21;23(4):2362. doi: 10.3390/ijms23042362.
5
Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.非规范 H3K79me2 依赖性途径促进 MLL 重排白血病的存活。
Elife. 2021 Jul 15;10:e64960. doi: 10.7554/eLife.64960.
6
Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.异基因干细胞移植消除了对伴有KMT2A部分串联重复的急性髓系白血病患者预后的负面影响。
Cancers (Basel). 2021 May 10;13(9):2272. doi: 10.3390/cancers13092272.
7
Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.急性髓系白血病的近期临床进展：聚焦表观遗传疗法
J Korean Med Sci. 2021 Apr 5;36(13):e85. doi: 10.3346/jkms.2021.36.e85.
8
DOT1L inhibitors block abnormal self-renewal induced by cohesin loss.DOT1L 抑制剂阻断黏连蛋白缺失诱导的异常自我更新。
Sci Rep. 2021 Mar 31;11(1):7288. doi: 10.1038/s41598-021-86646-9.
9
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of -Rearrangements: A Novel Therapeutic Strategy for Pediatric AML.抑制甲基转移酶DOT1L可使急性髓系白血病细胞对索拉非尼治疗敏感，与重排无关：一种针对儿童急性髓系白血病的新型治疗策略
Cancers (Basel). 2020 Jul 20;12(7):1972. doi: 10.3390/cancers12071972.
10
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.H3K79 甲基化的特定模式影响 AML 中癌基因的遗传相互作用。
Blood Adv. 2020 Jul 14;4(13):3109-3122. doi: 10.1182/bloodadvances.2020001922.
本文引用的文献
1
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.强效抑制 DOT1L 治疗 MLL 融合白血病。
Blood. 2013 Aug 8;122(6):1017-25. doi: 10.1182/blood-2013-04-497644. Epub 2013 Jun 25.
2
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.近年来在表观遗传学治疗方面的进展：以混合谱系白血病为例。
Blood. 2013 Jun 13;121(24):4847-53. doi: 10.1182/blood-2013-02-474833. Epub 2013 May 6.
3
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.MLL-AF6 融合癌基因导致白血病转化需要 H3K79 甲基转移酶 Dot1l。
Blood. 2013 Mar 28;121(13):2533-41. doi: 10.1182/blood-2012-11-465120. Epub 2013 Jan 29.
4
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.通过遗传灭活或药理学抑制 H3K79 甲基转移酶 Dot1l 来消除 MLL-AF10 和 CALM-AF10 介导的转化。
Leukemia. 2013 Apr;27(4):813-22. doi: 10.1038/leu.2012.327. Epub 2012 Nov 9.
5
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.急性髓系白血病中综合基因分析的预后相关性。
N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14.
6
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.60岁及以上初发细胞遗传学正常的急性髓系白血病成人患者中的MLL部分串联重复
Leukemia. 2012 Jul;26(7):1713-7. doi: 10.1038/leu.2012.34. Epub 2012 Feb 7.
7
A role for DOT1L in MLL-rearranged leukemias.DOT1L在MLL重排白血病中的作用。
Epigenomics. 2011 Dec;3(6):667-70. doi: 10.2217/epi.11.98.
8
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.MLL 重排白血病依赖 DOT1L 导致的异常 H3K79 甲基化。
Cancer Cell. 2011 Jul 12;20(1):66-78. doi: 10.1016/j.ccr.2011.06.010.
9
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.强效小分子 DOT1L 抑制剂选择性杀伤混合谱系白血病细胞。
Cancer Cell. 2011 Jul 12;20(1):53-65. doi: 10.1016/j.ccr.2011.06.009.
10
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.DOT1L，即 H3K79 甲基转移酶，是 MLL-AF9 介导白血病发生所必需的。
Blood. 2011 Jun 23;117(25):6912-22. doi: 10.1182/blood-2011-02-334359. Epub 2011 Apr 26.
Zotero 插件